Sanofi (Sanofi) Net Margin %

: 15.92% (As of Jun. 2023)

View and export this data going back to 2002. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Sanofi's Net Income for the six months ended in Jun. 2023 was $3,716 Mil. Sanofi's Revenue for the six months ended in Jun. 2023 was $23,342 Mil. Therefore, Sanofi's net margin for the quarter that ended in Jun. 2023 was 15.92%.

The historical rank and industry rank for Sanofi's Net Margin % or its related term are showing as below:

SNY' s Net Margin % Range Over the Past 10 Years
Min: 7.32 Med: 13.65 Max: 32.9
Current: 11.63

SNY's Net Margin % is ranked better than
72.28% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 3.76 vs SNY: 11.63

Sanofi Net Margin % Historical Data

The historical data trend for Sanofi's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

7.32

32.90

15.89

18.44

11.63

Sanofi Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Margin %																16.28	15.31	21.09	15.92	7.91

Competitive Comparison

For the Drug Manufacturers - General subindustry, Sanofi's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi Net Margin % Distribution

For the Drug Manufacturers industry and Healthcare sector, Sanofi's Net Margin % distribution charts can be found below:

* The bar in red indicates where Sanofi's Net Margin % falls into.

Sanofi Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Sanofi's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	5888.768	/	50647.764
	=	11.63 %

Sanofi's Net Margin for the quarter that ended in Jun. 2023 is calculated as

Net Margin	=	Net Income (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	3716.143	/	23342.362
	=	15.92 %

Sanofi (NAS:SNY) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Sanofi Net Margin % Related Terms

Thank you for viewing the detailed overview of Sanofi's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi (Sanofi) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:Mexico SANF:Italy 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SNW2:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SANO:Austria

Address

46, avenue de la Grande Armée, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.